Canary Capital

🎉 TWO MILLS, ONE BIG FUTURE FOR JEFFREYS FIND 🎉 We’re gearing up for a double banger run home for our Jeffreys Find Gold Mine! 🚀 First, the great news is that up to 120,000 tonnes of additional ore can be processed at Three Mile Hill Mill at Coolgardie✨ The first parcel of 40,000 tonnes starts in 10 days. Haulage has commenced. Then at the end of November, around 142,000 tonnes will be milled at Greenfields. That’s over 180,000 tonnes going through TWO mills, generating huge cash flows for AWJ💰 With the project wrapping up in early 2025, lots of cash is on the horizon from December onwards! 📈 And with gold prices soaring above AUD$4,150, we’re setting our sights way beyond our wildest dreams! Go Auric Mining Limited (ASX:AWJ) and Go! The Wonderful Goldfields of Western Australia🏆 Read the full announcement: https://lnkd.in/gwtcN_i6 #Gold #JeffreysFind #AuricMining #GoldRush #Mining #WesternAustralia #GoldMining #StockToWatch #AWJ #ASXNews #Resources #Exploration #GoldfieldsWA #MiningUpdates

🥇🥇 Can you walk us through the recent mining activities at the Maranoa deposit and the vat leach program? 🎬 Watch Resources + Energy Group (ASX:REZ) CEO & MD, Daniel Moore, as he shares insights from the front lines (Sound On 🎧) #gold #goldmining #mining #MiningNews #MiningStocks

Nyrada Inc. (ASX:NYR) today announces the results from supplementary preclinical studies confirming its lead drug candidate, NYR-BI03 prevents loss of function resulting from myocardial ischemia-reperfusion (IR) injury following myocardial infarction (heart attack) in rats. Nyrada CEO James Bonnar commented: “The confirmation of significant cardioprotective effects from NYR-BI03 in preclinical studies represents another milestone for Nyrada. Heart attacks affect 15-20 million people globally each year, with up to 15% mortality within 30 days due to complications like heart failure. Additionally, up to 50% of heart tissue damage is caused by reperfusion injury, where restoring blood flow after a heart attack paradoxically causes further damage to the heart. “The substantial improvements in heart function and structure shown in these supplementary studies are particularly encouraging as there are currently no FDA-approved therapies targeting ischemia-reperfusion injury. “We are excited to advance NYR-BI03 into clinical trials and believe it has the potential to transform the standard of care for heart attack survivors." More information at https://bit.ly/48mrN5t John Moore

Nyrada Inc. (ASX:NYR) has today announced that it has successfully completed Good Laboratory Practice safety studies of lead drug candidate NYR-BI03 indicating that it is well tolerated with a favourable safety profile. Nyrada is moving forward with its Human Ethics Research Committee submission, subject to which, Nyrada will initiate its first-in-human Phase I clinical trial for NYR-BI03 in late 2024. The Phase I trial, to be conducted in Australia, will provide valuable data applicable to both neuroprotection and cardioprotection programs. The trial is expected to continue until the second half of calendar 2025. Further information at https://bit.ly/3BMFoXL John Moore James Bonnar

📢 Resources + Energy Group (ASX:REZ) has received the necessary approvals from the Western Australia Department of Energy, Mines, Industry Regulation and Safety to commence a trial vat leach and bulk sample program at its East Menzies Gold Project. This approval includes the Maranoa deposit, which will be pivotal in providing material for the upcoming VAT leach testing. Link to Release: https://bit.ly/3NisEL0 REZ GROUP Managing Director J. Daniel Moore said: “This crucial approval to commence mining operations at East Menzies – at the Maranoa deposit represents a significant opportunity to advance our vat leach testing and achieve our first gold pour of this campaign. This is a major milestone for the company and our shareholders as we move closer to realising the full potential of the East Menzies Gold Project." #gold #mining #goldmining #goldproduction #preciousmetals

We're thrilled to announce our latest collaboration with Ericsson. As Max B. expressed "This collaboration goes beyond technology—it's about a commitment to innovation. We aim to empower enterprises by eliminating barriers to progress and ensuring their investments in Vision AI are future proof. Check out the official press release for all the details! https://lnkd.in/gfyFWR_N #Innovation #Collaboration #Ericsson #VisionAI

🎉Big News from Auric!🎉 We’ve now produced more than 7,500 ounces of gold from Jeffreys Find in 2024 and there’s so much more to come!🚀 In our latest 42-day gold milling campaign at Greenfields Mill, we struck gold with 6,295 ounces!🏅 And the cherry on top? We sold at a record-breaking A$3,859/ounce, our highest ever!💰 Check out those gold bars at the mill💛 Go Auric Mining Limited (ASX:AWJ) and Go! The wonderful goldfields of Western Australia🏆 Read the full announcement: https://lnkd.in/gkrrASZ8 #GoldRushWA #BreakingRecords #Gold #GoldMining #StockToWatch #AWJ #ASXNews 

Nyrada Inc. (ASX:NYR) today announced that its lead drug candidate demonstrated significant cardioprotection in a preclinical rat study. This is in addition to its already demonstrated efficacy in stroke. In this study, NYR-BI03 offered strong and statistically significant cardioprotection following a myocardial infarction with cardiac tissue damage reduced by 86 percent. NYR-BI03 additionally demonstrated superior efficacy in this study compared to Captopril, an FDA-approved therapy. This result broadens the potential therapeutic applications for NYR-BI03 to include coronary heart disease. The Global market for myocardial infarction therapies is anticipated to reach US$3.7 billion by 2032 offering an additional and significant market opportunity for Nyrada.  Nyrada continues to pioneer Transient Receptor Potential Canonical (TRPC) channel-blocking therapies and NYR-BI03 is first-in-class with a novel mechanism of action. More information available at https://bit.ly/47QujAD. John Moore James Bonnar